Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Phase II Conjugation Reactions: Overview

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Conjugated Proteins

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Extemporaneous Compounding, Pharmacy Preparations and Related Product Care in the Netherlands.

Pharmaceutics·2025

Same author

Enhanced Visualisation of Colorectal Tumours via Topical Application of EMI-137 in a Methylcellulose-Based Formulation: An ex vivo Feasibility Study.

Molecular imaging and biology·2025

Same author

Cardiac inotropy and cardiac calcium sensitization of PanLN800(-Forte), a cationic heptamethine indocyanine fluorescent contrast agent for intraoperative pan lymph node imaging.

Toxicology and applied pharmacology·2025

Same author

Non-Small Cell Lung Cancer Imaging Using a Phospholipase A2 Activatable Fluorophore.

Chemical & biomedical imaging·2024

Same author

Dose optimization of second window indocyanine green in meningioma patients.

Clinical neurology and neurosurgery·2024

Same author

Second window ICG predicts postoperative MRI gadolinium enhancement in high grade gliomas and brain metastases.

Neurosurgical focus: Video·2022

Search research articles

Related Experiment Video

Updated: May 22, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Kinase inhibitor conjugates.

Stefan Harmsen¹, Robbert Jan Kok

¹Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

Current Pharmaceutical Design

|May 11, 2012

Summary

This summary is machine-generated.

Kinase inhibitors are potent cancer drugs, but off-target effects and resistance limit their use. Conjugating these agents to carriers improves targeted delivery, enhancing treatment options for cancer and other diseases.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Experiment Videos

Last Updated: May 22, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Area of Science:

Oncology
Pharmacology
Drug Delivery

Background:

Kinase inhibitors represent a significant advancement in cancer therapy due to their potency and safety.
However, their clinical application is hampered by off-target toxicities and acquired resistance.
These limitations compromise the long-term efficacy of kinase inhibitor treatments.

Purpose of the Study:

To review strategies for overcoming the limitations of kinase inhibitors.
To highlight the role of carrier-mediated targeted delivery systems.
To explore the potential of targeted kinase inhibitors for various diseases.

Main Methods:

Review of current literature on kinase inhibitor conjugation and targeted delivery.
Analysis of approaches for cellular and intracellular targeting.
Discussion of disease applications beyond cancer.

Main Results:

Conjugation of kinase inhibitors to carriers facilitates targeted delivery.
Targeted delivery can mitigate off-target toxicities.
Targeted approaches show promise in overcoming drug resistance.

Conclusions:

Targeted delivery systems offer a promising strategy to enhance the therapeutic index of kinase inhibitors.
This approach holds potential for treating not only cancer but also other diseases driven by deregulated kinase signaling.
Further development of targeted kinase inhibitors could lead to more effective and safer treatment options.